Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18097910 | 0.81 | ALDH1A1 (0.61) | ALDH1A1HPGDMAOALMNAKDM4E | |
| SCHEMBL29191666 | 0.81 | PARP14 (0.49) | ALDH1A1HPGDMAOALMNAKDM4E | |
| SCHEMBL12985612 | 0.79 | SMN1; SMN2 (0.47) | ALDH1A1HPGDMAOALMNAKDM4E | |
| SCHEMBL30368335 | 0.78 | ALDH1A1 (0.52) | ALDH1A1HPGDMAOALMNAHDAC1 | |
| SCHEMBL1430696 | 0.78 | ALDH1A1 (0.52) | ALDH1A1HPGDMAOALMNAHDAC1 | |
| SCHEMBL14576915 | 0.78 | L3MBTL1 (0.43) | ALDH1A1HPGDKDM4ESMN1; SMN2RAB9A | |
| SCHEMBL29408738 | 0.77 | RAB9A (0.69) | ALDH1A1HPGDLMNAKDM4ESMN1; SMN2 | |
| SCHEMBL1430533 | 0.77 | RAB9A (0.69) | ALDH1A1HPGDLMNAKDM4ESMN1; SMN2 | |
| SCHEMBL30002532 | 0.77 | SMN1; SMN2 (0.61) | ALDH1A1HPGDMAOALMNAHDAC1 | |
| SCHEMBL6379676 | 0.77 | ALDH1A1 (0.50) | ALDH1A1HPGDMAOALMNAHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220213100-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE REGULATOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2022-07-07 | — | — | US | disclosed |
| US-20120135975-A1 | Substituted Esters as Cannabinoid-1 Receptor Modulators | MERCK & CO., INC. (US) | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213100-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE REGULATOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | KRAS, NRAS, GNAQ | ALDH1A1 2591/4885HPGD 536/4885MAOA 3593/4885 |
| US-20120135975-A1 | Substituted Esters as Cannabinoid-1 Receptor Modulators | CNR1, CNR2, FAAH | ALDH1A1 2986/4885HPGD 3445/4885MAOA 703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.